Effect of raloxifene and hormone therapy on serum markers of brain and whole-body cholesterol metabolism in postmenopausal women

Maturitas

Volumn 50, Issue 4, 2005, Pages 312-320

  Vogelvang, Tatjana E ^a   Mijatovic, Velja ^a   Van Der Mooren, Marius J ^a   Pinsdorf, Ursula ^b   Von Bergmann, Klaus ^b   Netelenbos, J Coen ^a   Lütjohann, Dieter ^b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF BONN   (Germany)

Author keywords

24S Hydroxycholesterol (cerebrosterol); Campesterol; Cholesterol; Hormone therapy; Lathosterol; Menopause; Raloxifene

Indexed keywords

24 HYDROXYCHOLESTEROL; CAMPESTEROL; CHOLESTEROL; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; LATHOSTEROL; PHYTOSTEROL; RALOXIFENE; STEROL DERIVATIVE; UNCLASSIFIED DRUG;

ABSORPTION; ADULT; ARTICLE; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CHOLESTEROL SYNTHESIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; FEMALE; GAS CHROMATOGRAPHY; HORMONAL THERAPY; HUMAN; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; NORMAL HUMAN; POSTMENOPAUSE; RETROSPECTIVE STUDY;

EQUIDAE;

EID: 14944341463     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2004.08.004     Document Type: Article

References (45)

1. D. Lütjohann, O. Breuer, and G. Ahlborg Cholesterol homeostasis in human brain: evidence for an age-dependent flux of 24S-hydroxycholesterol from the brain into the circulation Proc. Natl. Acad. Sci. U.S.A. 93 1996 9799 9804
2. 2 techniques in vivo and in vitro J. Biol. Chem. 272 1997 30178 30184
3. I. Björkhem, D. Lütjohann, U. Diczfalusy, L. Ståhle, G. Ahlborg, and J. Wahren Cholesterol homeostasis in human brain: turnover of 24S-hydroxycholesterol and evidence for a cerebral origin of most of this oxysterol in the circulation J. Lipid Res. 39 1998 1594 1600
4. E.G. Lund, J.M. Guileyardo, and D.W. Russell cDNA cloning of cholesterol 24-hydroxylase, a mediator of cholesterol homeostasis in the brain Proc. Natl. Acad. Sci. U.S.A. 96 1999 7238 7243
5. E.G. Lund, C. Xie, T. Kotti, S.D. Turley, J.M. Dietschy, and D.W. Russell Knockout of the cholesterol 24-hydroxylase gene in mice reveals a brain-specific mechanism of cholesterol turnover J. Biol. Chem. 278 2003 22980 22988
6. D. Lütjohann, A. Papassotiropoulos, and I. Björkhem Plasma 24S-hydroxycholesterol (cerebrosterol) is increased in Alzheimer and vascular demented patients J. Lipid Res. 41 2000 195 198
7. L. Bretillon, A. Sidén, and L.O. Wahlund Plasma levels of 24S-hydroxycholesterol in patients with neurological diseases Neurosci. Lett. 293 2000 87 90
8. A. Papassotiropoulos, D. Lütjohann, and M. Bagli Plasma 24S-hydroxycholesterol: a peripheral indicator of neuronal degeneration and potential state marker for Alzheimer's disease NeuroReport 11 2000 1959 1962
9. H. Kölsch, M. Ludwig, D. Lütjohann, and M.L. Rao Neurotoxicity of 24-hydroxycholesterol, an important cholesterol elimination product of the brain, may be prevented by Vitamin E and estradiol-17 J. Neural Transm. 108 2001 475 488
10. H. Xu, G.K. Gouras, and J.P. Greenfield Estrogen reduces neuronal generation of Alzheimer beta-amyloid peptides Nat. Med. 4 1998 447 451
11. K. Andersen, L.J. Launer, and M.E. Dewey Gender differences in the incidence of AD and vascular dementia: the EURODEM Studies EURODEM Incidence Research Group Neurology 53 1999 1992 1997
12. E.S. LeBlanc, J. Janowsky, B.K. Chan, and H.D. Nelson Hormone replacement therapy and cognition: systematic review and meta-analysis J. Am. Med. Assoc. 285 2001 1489 1499
13. K. Yaffe, G. Sawaya, I. Lieberburg, and D. Grady Estrogen therapy in postmenopausal women: effects on cognitive function and dementia J. Am. Med. Assoc. 279 1998 688 695
14. E. Hogervorst, K. Yaffe, M. Richards, and F. Huppert Hormone replacement therapy to maintain cognitive function in women with dementia Cochrane Database Syst. Rev. 2002 CD003799
15. S.A. Shumaker, C. Legault, and L. Thal Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study A randomized controlled trial J. Am. Med. Assoc. 289 2003 2651 2662
16. P.P. Zandi, M.C. Carlson, and B.L. Plassman Hormone replacement therapy and incidence of Alzheimer disease in older women: the Cache County Study J. Am. Med. Assoc. 288 2002 2123 2129
17. M.I. Geerlings, A. Ruitenberg, and J.C. Witteman Reproductive period and risk of dementia in postmenopausal women J. Am. Med. Assoc. 285 2001 1475 1481
18. T. Nickelsen, E.G. Lufkin, B.L. Riggs, D.A. Cox, and T.H. Crook Raloxifene hydrochloride, a selective estrogen receptor modulator: safety assessment of effects on cognitive function and mood in postmenopausal women Psychoneuroendocrinology 24 1999 115 128
19. K. Yaffe, K. Krueger, and S. Sarkar Cognitive function in postmenopausal women treated with raloxifene N. Engl. J. Med. 344 2001 1207 1213
20. M.S. Post, M.J. van der Mooren, W.M. van Baal, S.J.M. Neele, J.C. Netelenbos, and P. Kenemans Raloxifene reduces impedance to flow within the uterine artery in early postmenopausal women: a 2-year randomized, placebo-controlled, comparative study Am. J. Obstet. Gynecol. 185 2001 557 562
21. Smolders RGV, T.E. Vogelvang, and V. Mijatovic A 2-year, randomized, comparative, placebo-controlled study on the effects of raloxifene on lipoprotein(a) and homocysteine Maturitas 41 2002 105 114
22. T.E. Vogelvang, V. Mijatovic, and O. Kamp Neither long-term treatment with raloxifene nor hormone replacement therapy modulate cardiac function in healthy postmenopausal women: two randomized, placebo-controlled, 2-year studies Am. J. Obstet. Gynecol. 186 2002 729 736
23. T.E. Vogelvang, J.R. Leurs, and M.J. van der Mooren Raloxifene reduces procarboxypeptidase U, an antifibrinolytic marker A 2-year randomized, placebo-controlled study in healthy early postmenopausal women Menopause 11 2004 110 115
24. D. Lütjohann, A. Brzezinka, and E. Barth Profile of cholesterol-related sterols in aged amyloid precursor protein transgenic mouse brain J. Lipid Res. 43 2002 1078 1085
25. D. Lütjohann Sterol autoxidation: from phytosterols to oxyphytosterols Br. J. Nutr. 91 2004 3 4
26. P.D. Delmas, N.H. Bjarnason, and B.H. Mitlak Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women N. Engl. J. Med. 337 1997 1641 1647
27. S.R. Goldstein, W.H. Scheele, S.K. Rajagopalan, J.L. Wilkie, B.W. Walsh, and A.K. Parsons A 12-month comparative study of raloxifene, estrogen, and placebo on the postmenopausal endometrium Obstet. Gynecol. 95 2000 95 103
28. B. Ettinger, D.M. Black, and B.H. Mitlak Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators J. Am. Med. Assoc. 282 1999 637 645
29. S.R. Cummings, S. Eckert, and K.A. Krueger The effect of raloxifene on risk of breast cancer in postmenopausal women - results from the MORE randomized trial J. Am. Med. Assoc. 281 1999 2189 2197
30. D. Agnusdei, S. Liu-Leage, and B. Augendre-Ferrante Results of international clinical trials with raloxifene Ann. Endocrinol. 60 1999 242 246
31. V. De Leo, A. La Marca, G. Morgante, D. Lanzetta, C. Setacci, and F. Petraglia Randomized control study of the effects of raloxifene on serum lipids and homocysteine in older women Am. J. Obstet. Gynecol. 184 2001 350 353
32. B.W. Walsh, L.H. Kuller, and R.A. Wild Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women J. Am. Med. Assoc. 279 1998 1445 1451
33. V. Mijatovic, M.J. van der Mooren, P. Kenemans, G.W. de Valk-de Roo, and J.C. Netelenbos Raloxifene lowers serum lipoprotein(a) in healthy postmenopausal women A randomized, double-blind, placebo-controlled comparison with conjugated equine estrogens Menopause 6 1999 134 137
34. G.W. De Valk-de Roo, Stehouwer CDA, and P. Meijer Both raloxifene and estrogen reduce major cardiovascular risk factors in healthy postmenopausal women: a 2-year, placebo-controlled study Arterioscler. Thromb. Vasc. Biol. 19 1999 2993 3000
35. T. Sudhop, D. Lutjohann, and A. Kodal Inhibition of intestinal cholesterol absorption by ezetimibe in humans Circulation 106 2002 1943 1948
36. B. Wolozin, W. Kellman, P. Ruosseau, G.G. Celesia, and G. Siegel Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3- methyglutaryl coenzyme A reductase inhibitors Arch. Neurol. 57 2000 1439 1443
37. H. Jick, G.L. Zornberg, S.S. Jick, S. Seshadri, and D.A. Drachman Statins and the risk of dementia Lancet 356 2000 1627 1631
38. K. Rockwood, S. Kirkland, and D.B. Hogan Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people Arch. Neurol. 59 2002 223 227
39. K. Yaffe, E. Barrett-Connor, F. Lin, and D. Grady Serum lipoprotein levels, statin use, and cognitive function in older women Arch. Neurol. 59 2002 378 384
40. S. Locatelli, D. Lütjohann, H.H. Schmidt, C. Otto, U. Beisiegel, and K. von Bergmann Reduction of plasma 24S-hydroxycholesterol (cerebrosterol) levels using high-dosage simvastatin in patients with hypercholesterolemia: evidence that simvastatin affects cholesterol metabolism in the human brain Arch. Neurol. 59 2002 213 216
41. K. Fassbender, M. Stroick, and T. Bertsch Effects of statins on human cerebral cholesterol metabolism and secretion of Alzheimer amyloid peptide Neurology 59 2002 1257 1258
42. M. Simons, F. Schwärzler, and D. Lütjohann Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: a 26-week randomized, placebo-controlled, double-blind trial Ann. Neurol. 52 2002 346 350
43. G.L. Vega, M.F. Weiner, and A.M. Lipton Reduction in levels of 24S-hydroxycholesterol by statin treatment in patients with Alzheimer disease Arch. Neurol. 60 2003 510 515
44. A.O. Mueck, H. Seeger, F.U. Deuringer, and D. Wallwiener Effect of an estrogen/statin combination on biochemical markers of endothelial function in human coronary artery cell cultures Menopause 8 2001 216 221
45. G.M. Darling, J.A. Johns, P.I. McCloud, and S.R. Davis Concurrent use of simvastatin and estrogen-progestin therapy compared with each therapy alone for hypercholesterolemia in postmenopausal women Climacteric 2 1999 181 188